Arthneeti

Coral Laboratories Share Price & Earnings Call Analysis

₹499.00-0.14% today
Market cap
₹178 Cr
P/E
9.39
ROE
7.79%
PEG
0.27
Price to sales
1.85
Debt to equity
0.02
52W high / low
₹665 / ₹362
Sales growth (5Y)
-2.31%
EBITDA margin
19.15%
Net profit margin
18.60%
Promoter holding
71.51%
Sales (last year)
₹97 Cr

Potential multibaggers · Q2 FY27

Potential multibaggers in Pharmaceuticals & Biotechnology
on management's own guidance

  1. Strong growth
    2
  2. Strong growth
    1
  3. Strong growth
    3
See all potential multibaggersWhere does Coral Laboratories rank?

Portfolio builder

Build your portfolio
from the top-ranked stocks

  1. 1. Pick 3–15 stocks
  2. 2. Choose large, mid or small cap and your sectors
  3. 3. Get a portfolio built from the rankings
Build my portfolio

Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.

Peers

Pharmaceuticals & Biotechnology companies ranked on guidance

#CompanyRevenue guidedMargin guidedMarket capP/E
140%+Up 2%+₹480 Cr19.1
240%+Up 0–2%₹212 Cr16.1
340%+Flat₹17,925 Cr—
440%+Flat₹5,223 Cr39.1
540%+Flat₹4,268 Cr—
640%+Flat₹40 Cr—

Sign up free to see every company in the sector ranking and track Coral Laboratories.

Pro shows every company guiding 40%+ revenue growth →Full Pharmaceuticals & Biotechnology ranking

Financials of Coral Laboratories

Quarterly Results, Profit & Loss, Balance Sheet, Cash Flows, and Ratios are shown below as separate sections.

Financials of Coral Laboratories

Quarterly Results

Quarter-by-quarter operating performance

Dec 2022Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025
Sales +24.7311.4413.5523.1518.0828.8931.6632.2322.9928.1318.8219.0321.56
Expenses +23.8813.5211.8117.0015.9822.6420.9225.7216.6725.4416.6414.0919.67
Operating Profit0.85-2.081.746.152.106.2510.746.516.322.692.184.941.89
OPM %3.44%-18.18%12.84%26.57%11.62%21.63%33.92%20.20%27.49%9.56%11.58%25.96%8.77%
Other Income +1.541.161.291.811.372.001.562.542.521.712.053.032.49
Interest0.110.020.000.000.000.000.030.010.020.040.060.100.00
Depreciation0.500.680.550.440.490.500.490.510.500.510.450.450.69
Profit before tax1.78-1.622.487.522.987.7511.788.538.323.853.727.423.69
Tax %51.69%-45.06%26.21%20.21%27.52%25.16%25.21%25.21%26.08%26.49%31.18%21.56%24.93%
Net Profit +0.86-0.891.846.002.165.798.806.386.142.832.565.822.78
EPS in Rs2.41-2.495.1516.796.0516.2124.6317.8617.197.927.1716.297.78

Financials of Coral Laboratories

Profit & Loss

Annual income statement trend

Mar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025TTM
Sales +515977959291719776788411588
Expenses +41476072777965816774678976
Operating Profit10121623151251684162612
OPM %20%21%21%24%17%14%8%16%11%5%19%23%13%
Other Income +1333456467689
Interest0000000000000
Depreciation1322222222222
Profit before tax101217251816918128213219
Tax %21%22%29%34%31%34%22%23%24%22%24%26%
Net Profit +8101216121071496162414
EPS in Rs22.0326.7934.7145.6334.8528.6119.9637.9325.3318.0544.2067.6339.16
Dividend Payout %9%9%9%11%6%7%0%0%0%0%0%0%

Financials of Coral Laboratories

Balance Sheet

Capital structure and asset base

Mar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Sep 2025
Equity Capital4444444444444
Reserves475667106113110112133152151174198210
Borrowings +0102216660041
Other Liabilities +10121920222123252820282519
Total Liabilities607289131140136144168190174206229233
Fixed Assets +20191818222323212425242324
CWIP00000000200214
Investments11539452825334641505257
Other Assets +40526774738497112118108132152138
Total Assets607289131140136144168190174206229233

Financials of Coral Laboratories

Cash Flows

Operating, investing and financing cash movement

Mar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025
Cash from Operating Activity +1051113-1-41613-5-1
Cash from Investing Activity +1-0-3-10-133-2-0-6-31-0
Cash from Financing Activity +0-0-00-3-1400-603
Net Cash Flow2-021-21-2104-41
Free Cash Flow1-1499-4-5-0111-6-4
CFO/OP29%30%70%85%124%31%-59%28%127%383%-4%23%

Financials of Coral Laboratories

Ratios

Working capital efficiency and return ratios

Mar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025
Debtor Days109152132117125122178148184109123107
Inventory Days9711011015512011617615816910014968
Days Payable616680758791129108813413046
Cash Conversion Cycle145196162197157146225198272176142129
Working Capital Days158194179164161171241178222221183140
ROCE %21%22%27%28%16%13%8%13%7%5%13%17%

Continue your research

Others in Pharmaceuticals & Biotechnology this season

  • Anthem Bioscienc (Q2 FY27)

    Q2FY27 Consolidated Revenue from Operations: ₹5,940 Mn, up 7.9% YoY from ₹5,505 Mn in Q2FY26 (Page 4). Key investor presentation takeaways from Anthem Bioscienc

  • Neuland Laboratories (Q2 FY27)

    Q2FY27 Total Income (revenue) was ₹457.2 crore, down 11.4% year-on-year (YoY) from Q2FY26. Key investor presentation takeaways from Neuland Laboratories Ltd's Q

  • Hikal (Q2 FY27)

    Consolidated Revenue Q2FY27:** ₹434 crores, up 36% YoY from ₹319 crores in Q2FY26 (Page 9) . Key investor presentation takeaways from Hikal Ltd's Q2 FY27 invest

  • Kopran (Q2 FY27)

    9,335 lakhs (~79% increase) . Key investor presentation takeaways from Kopran Ltd's Q2 FY27 investor presentation — and how it ranks against sector peers.

Compare:vs Sun Pharmaceutical Industriesvs Divis Laboratoriesvs Torrent Pharmaceuticals